 Subjects -> NUTRITION AND DIETETICS (Total: 201 journals)
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z | | We no longer collect new content from this publisher because the publisher has forbidden systematic access to its RSS feeds. |
|
|
- Nutritional Training Increases Long-term Fruit and Vegetable Consumption
in Women with Early Breast Cancer – A Randomized Controlled Trial
Authors: Arends; J., Theobald, S., Schmid, J., Bartsch, H. H.
Abstract: After primary treatment of early breast cancer many women want to change their dietary habits and this may influence disease recurrence. The aim of the study was to increase fruit and vegetable (FV) intake for at least 6 months in women with early breast cancer by a short modular nutritional training program and offering refresher sessions. Design: Single-centre randomized controlled study in women attending an in-hospital cancer rehabilitation program. Subjects in the intervention group (INT) participated in a 2-week structured nutritional training program and were invited to visit brief refresher courses after 3 and 6 months. Women in the control group (CON) were offered standard nutritional advice. All subjects completed 4-day food records before arrival (baseline), and 1, 3 and 6 months after the start of the study. Of 152 women included in the study complete follow-up was available for 118. Consumption of FV (mean±SD) was similar at baseline (INT 483±235, CON 460±177 g/d) but only increased in the intervention group and at all follow-up times (1 month: 743±287 vs. 526±177; 3 months: 673±246 vs. 485±169; 6 months: 631±222 vs. 505±172 g/d; p
Citation: Metab Nutr Oncol ; : -
PubDate: 2014-12-05T12:36:06+0100
DOI: 10.1055/s-0034-1395671
- Retrospective Study of Body Weight in Patients with Multiple Myeloma
through Different Stages of the Disease
Authors: Talamo; G., Zhu, J., Dolloff, N. G., Lamparella, N. E., Joshi, M., Barochia, A., Drabick, J. J., Malysz, J.
Abstract: Little is known regarding body weight changes in patients with multiple myeloma (MM) during the course of their disease, and the influence of obesity in the overall survival (OS) of patients affected by this cancer.We retrospectively collected clinical data from 318 MM patients, and analyzed their weight and body mass index (BMI) at various points throughout the course of the disease, including baseline, pre- and post-peripheral blood stem cell transplant (PBSCT), and time of death.At the time of diagnosis, median BMI was 28.1 (±5.7 SD; range, 15.3–51.8). The majority of MM patients were either overweight or obese, both at the time of initial diagnosis (80%) and in the terminal phase of the disease (66%). Only 5% of patients had malnutrition at the time of death. Median body weight was 81.5 and 79.4 kg before and 6 weeks after high-dose chemotherapy and PBSCT (p
Citation: Metab Nutr Oncol ; : -
PubDate: 2013-12-16T12:59:30+0100
DOI: 10.1055/s-0033-1358760
- Decreased Plasma Ascorbate Levels in Stage IV Melanoma Patients
Authors: Schleich; T., Rodemeister, S., Venturelli, S., Sinnberg, T., Garbe, C., Busch, C.
Abstract: It has been reported that cancer patients frequently express low ascorbate (ascorbic acid, vitamin C) blood levels. However, so far this was not shown for melanoma patients.Total ascorbate (TAA) levels were determined in plasma of healthy control individuals (n=31, mean age: 47.3 years, TAA: 64.86 µM) and in 126 melanoma patients (stage I: n=30, mean age: 51 years, TAA: 59.95 µM; stage II: n=30, mean age: 46.8 years, TAA: 58.85 µM; stage III: n=32, mean age: 48.6 years, TAA: 57.27 µM; stage IV: n=34, mean age: 51.1 years, TAA: 47.16 µM). Plasma TAA levels in stage IV patients were significantly reduced by 27.3% when compared to healthy individuals (p=0.0001, t-test). The reduced plasma TAA levels in stage IV patients negatively correlated with increased S100 and lactate dehydrogenase (LDH) levels. Further, plasma TAA levels were determined in additional 9 stage IV patients directly before and 24 h after intravenous polychemotherapy (carboplatin+paclitaxel, n=5) or immunotherapy (ipilimumab, n=4). TAA levels significantly decreased 24 h after therapy (mean TAA before therapy: 48.7 µM; mean TAA after therapy: 43.0 µM; 11.4% reduction, p
Citation: Metab Nutr Oncol ; : -
PubDate: 2013-06-25T10:36:46+01:00
DOI: 10.1055/s-0033-1348256
- It’s Time for a New Journal!
Metab Nutr Oncol
DOI: 10.1055/s-0033-1334960
© Georg Thieme Verlag KG Stuttgart · New York
Artikel in Thieme eJournals:
Inhaltsverzeichnis open access Volltext
Metab Nutr Oncol ; : -2013-02-27T07:37:32+0100
|
Open Access journal
